On May 27, 2026, MetaVia, Inc. (MTVA) announced the presentation of new Phase 1 data for DA-1726, the company's oxyntomodulin analog targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR). The data were presented in a late-breaking poster session at the European Association for the Study of the Liver Congress 2026 (EASL 2026). The data show that DA-1726 was generally well tolerated up to the 48 mg dose level with gastrointestinal adverse events primarily mild-to-moderate and transient. In addition, there were no clinically meaningful changes in cardiovascular parameters, including heart rate and QTcF, something that has been an issue for other compounds that target GCGR. The company is continuing the Phase 1 Part 3a/3b titration studies of DA-1726 at higher dose levels and we continue to anticipate topline data in the fourth quarter of 2026.
